BUGWORKS is a drug discovery company that aims to discover novel biopharmaceutical assets for the treatment of Antimicrobial Resistance (AMR)

Who We are ?

A strong inter-disciplinary team with competencies in Entrepreneurship, Mathematics, Engineering, IT, Biochemistry, Microbiology, Molecular Biology, Pharmacology and Medicinal Chemistry.

What We Do ?

Towards treatment of AMR, we have developed a stealth strategy to avoid efflux liability and a potentiation strategy that enables the entry of antibiotics into Gram negative pathogens; two key barriers that need to be overcome for developing the next generation of successful antibiotics.

Why We Do ?

  • Centers for Disease Control (CDC) estimates that 1 in 25 patients worldwide will acquire an infection as a result of their hospital stay
  • 10 million deaths will occur worldwide if antibiotic resistance is left unchecked, costing the world $100 trillion by 2050
  • The antibiotic pipeline lack new mechanisms against drug resistant Gram negative bacteria